Time dependent mean field theory of the superfluid-insulator phase transition

We develop a time-dependent mean field approach, within the time-dependent variational principle, to describe the Superfluid-Insulator quantum phase transition. We construct the zero temperature phase diagram both of the Bose-Hubbard model (BHM), and of a spin-S Heisenberg model (SHM) with the XXZ anisotropy. The phase diagram of the BHM indicates a phase transition from a Mott insulator to a compressibile superfluid phase, and shows the expected lobe-like structure. The SHM phase diagram displays a quantum phase transition between a paramagnetic and a canted phases showing as well a lobe-like structure. We show how the BHM and Quantum Phase model (QPM) can be rigorously derived from the SHM. Based on such results, the phase boundaries of the SHM are mapped to the BHM ones, while the phase diagram of the QPM is related to that of the SHM. The QPM's phase diagram obtained through the application of our approach to the SHM, describes the known onset of the macroscopic phase coherence from the Coulomb blockade regime for increasing Josephson coupling constant. The BHM and the QPM phase diagrams are in good agreement with Quantum Monte Carlo results, and with the third order strong coupling perturbative expansion.Comment: 15 pages, 8 figures. To be published in Phys. Rev.

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362